SCHEMBL25599074

SCHEMBL25599074

C=C1CC(C)CC(CC[C@H](NC(=O)c2ccc3c(OC)cccc3c2OCc2ccc(C(F)(F)F)cc2)C(=O)O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIFC1 Q9BW19 2/20 0.39
CXCR2 P25025 1/20 0.39
ITGB1 P05556 2/20 0.35
ITGA4 P13612 2/20 0.35
MRGPRX4 Q96LA9 3/20 0.34
MME P08473 1/20 0.34
ACE P12821 1/20 0.34
CPA1 P15085 1/20 0.34
ACE2 Q9BYF1 1/20 0.34
TGM2 P21980 1/20 0.34
ITGB7 P26010 1/20 0.34
PPARA Q07869 6/20 0.34
PPARD Q03181 2/20 0.34
TACR1 P25103 1/20 0.33
GPR132 Q9UNW8 1/20 0.33
YAP1 P46937 1/20 0.33
PPARG P37231 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25599003 0.92 CXCR2 (0.40) KIFC1CXCR2MRGPRX4MMEACE
SCHEMBL25599374 0.89 CXCR2 (0.51) KIFC1CXCR2MRGPRX4MMEACE
SCHEMBL25599284 0.89 CXCR2 (0.51) KIFC1CXCR2MRGPRX4MMEACE
SCHEMBL25599235 0.87 CXCR2 (0.40) KIFC1CXCR2MMEACECPA1
SCHEMBL25599016 0.86 CXCR2 (0.41) KIFC1CXCR2MRGPRX4MMEACE
SCHEMBL25599423 0.86 CXCR2 (0.41) KIFC1CXCR2MRGPRX4MMEACE
SCHEMBL25599229 0.86 CXCR2 (0.41) KIFC1CXCR2MRGPRX4MMEACE
SCHEMBL25599106 0.85 CXCR2 (0.42) KIFC1CXCR2MRGPRX4MMEACE
SCHEMBL25599537 0.84 CXCR2 (0.41) KIFC1CXCR2ITGB1ITGA4MRGPRX4
SCHEMBL25599570 0.84 CXCR2 (0.40) KIFC1CXCR2MMEACECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA KIFC1 4789/4885CXCR2 1205/4885ITGB1 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.